News & Updates

Show Multimedia Only

PASCAL System augments treatment armamentarium for severe mitral regurgitation

06 Oct 2022 by

In the CLASP* IID trial, the PASCAL Transcatheter Valve Repair System demonstrated noninferiority to the MitraClip System for the treatment of severe symptomatic degenerative mitral regurgitation (DMR).

PASCAL System augments treatment armamentarium for severe mitral regurgitation

06 Oct 2022

Smartphone app fails to boost MVPA in diabetics

06 Oct 2022 by

Among patients with type 2 diabetes (T2D), use of the smartphone-based app InterWalk does not improve objective measures of moderate-to-vigorous physical activity (MVPA), according to a study.

Smartphone app fails to boost MVPA in diabetics

06 Oct 2022

Sensitization, dermatitis prevalent among workers highly exposed to epoxy

06 Oct 2022

Skin sensitization and dermatitis appear to be common among workers exposed to high concentrations of epoxy, despite comprehensive skin protection, according to a study.

Sensitization, dermatitis prevalent among workers highly exposed to epoxy

06 Oct 2022

Robot-assisted laparoscopic pyeloplasty tied to better recovery in kids

06 Oct 2022

For the treatment of ureteropelvic junction obstruction (UPJO) in infants and young children, robotic-assisted laparoscopic pyeloplasty (RALP) leads to less trauma and better recovery while reaching comparable efficacy as conventional LP, a recent study has found.

Robot-assisted laparoscopic pyeloplasty tied to better recovery in kids

06 Oct 2022

Underweight people at greater risk of tuberculosis

06 Oct 2022

There appears to be an inverse correlation between body mass index (BMI) and the risk of tuberculosis, especially in the underweight population, a recent study has found.

Underweight people at greater risk of tuberculosis

06 Oct 2022

Original New Drug Application Approvals by US FDA (16 - 30 Sep 2022)

06 Oct 2022

New drug applications approved by US FDA as of 16-30 Sep 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16 - 30 Sep 2022)

06 Oct 2022

Ligelizumab safe, effective in patients with chronic spontaneous urticaria

06 Oct 2022 by

Ligelizumab, a next-generation anti-IgE antibody, is safe and effective in treating patients with H₁-antihistamine (H₁-AH) refractory chronic spontaneous urticaria (CSU), according to two phase III studies presented at EADV 2022.